MedTrace Logo

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

NCT05066685 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18457

Last updated 2021-10-12

No results posted yet for this study

Summary

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.

Conditions

  • Age-related Macular Degeneration (AMD)

Interventions

OTHER

All participants

All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-11
Primary Completion
2020-09-25
Completion
2020-09-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05066685 on ClinicalTrials.gov